PIN1-targeting treatment for pancreatic cancer
Full Project 2
Researchers are developing a new drug that blocks PIN1 to try to overcome treatment resistance in people with pancreatic cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Riverside NIH-funded |
| Lab location | 1 site (Riverside, United States) |
| Project ID | NIH-11179214 on NIH RePORTER |
What this research studies
Scientists at UC Riverside and City of Hope will design and chemically create new molecules that block the PIN1 protein, which is often overactive in pancreatic tumors. They will test the best compounds in pancreatic cancer cells grown in the lab and in mouse models to see whether tumors shrink and the tumor microenvironment becomes less suppressive. The team will study how the drugs work at the molecular level and measure how the body absorbs and clears them in mice. Promising compounds would be refined for safety and effectiveness before any future human testing.
Who could benefit from this research
Good fit: People with pancreatic ductal adenocarcinoma, especially those whose tumors show high PIN1 activity or who have few treatment options, could be candidates for future trials.
Not a fit: Patients seeking immediate treatment or whose tumors do not rely on PIN1 are unlikely to benefit directly from this preclinical research.
Why it matters
Potential benefit: If successful, this work could lead to new medicines that overcome resistance and offer better treatment options for people with pancreatic cancer.
How similar studies have performed: Other lab and animal studies targeting PIN1 or similar pathways have shown encouraging results, but PIN1-targeting drugs are not yet approved for patients.
Where this research is happening
Riverside, United States
- University of California Riverside — Riverside, United States (Active)
Researchers
- Principal investigator: Pellecchia, Maurizio — University of California Riverside
- Study coordinator: Pellecchia, Maurizio
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.